What Monte Rosa Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 1 | 37 |
| Total trades | 1 | 63 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 362,460 |
| Disposed | 13 | 1,222,824 |
| Net activity | −13 | −860,364 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Bowen Matthew | Principal Accounting Officer | Oct 05 | Open-market sale · S | −13 | $10.56 | −$137 | 25,891 |
| Warmuth Markus | President & CEO | Jul 16 | Open-market sale · S | −9,500 | $23.18 | −$220K | 585,038 |
| Champoux Jennifer | Chief Operating Officer | Jul 15 | Open-market sale · S | −4,351 | $23.38 | −$102K | 62,371 |
| Champoux Jennifer | Chief Operating Officer | Jul 15 | Exercise / conversion · M | +4,351 | $3.98 | +$17.3K | 66,722 |
| Townson Sharon | Chief Scientific Officer | Jul 06 | Open-market sale · S | −400 | $24.13 | −$9.65K | 67,845 |
| Townson Sharon | Chief Scientific Officer | Jul 06 | Open-market sale · S | −5,600 | $23.25 | −$130K | 68,245 |
| Townson Sharon | Chief Scientific Officer | Jul 06 | Exercise / conversion · M | +6,000 | $6.14 | +$36.8K | 73,845 |
| Behbahani Ali | Director | Jul 01 | Other Transaction · J | −15,000 | — | — | 0 |
| Behbahani Ali | Director | Jul 01 | Other Transaction · J | +15,000 | — | — | 15,000 |
| Behbahani Ali | Director | Jul 01 | Other Transaction · J | −1,000,000 | — | — | 6,692,298 |
| Janku Filip | Chief Medical Officer | Jun 30 | Open-market sale · S | −5,407 | $24.50 | −$132K | 60,612 |
| Janku Filip | Chief Medical Officer | Jun 30 | Exercise / conversion · M | +5,407 | $13.41 | +$72.5K | 66,019 |
| Manning Anthony M. | Director | Jun 29 | Open-market sale · S | −10,000 | $23.11 | −$231K | 0 |
| Manning Anthony M. | Director | Jun 29 | Exercise / conversion · M | +10,000 | $4.16 | +$41.6K | 10,000 |
| Janku Filip | Chief Medical Officer | Jun 29 | Open-market sale · S | −6,000 | $22.95 | −$138K | 59,992 |
| Janku Filip | Chief Medical Officer | Jun 29 | Exercise / conversion · M | +6,000 | $7.56 | +$45.4K | 65,992 |
| Janku Filip | Chief Medical Officer | Jun 24 | Open-market sale · S | −30,000 | $21.42 | −$643K | 59,992 |
| Janku Filip | Chief Medical Officer | Jun 24 | Exercise / conversion · M | +30,000 | $7.56 | +$227K | 89,992 |
| Janku Filip | Chief Medical Officer | Jun 23 | Open-market sale · S | −11,845 | $20.22 | −$240K | 59,992 |
| Janku Filip | Chief Medical Officer | Jun 23 | Exercise / conversion · M | +6,000 | $7.56 | +$45.4K | 71,837 |
Loading...
